Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Bronchopulmonary aspergillosis? 246 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 246 reports of Bronchopulmonary aspergillosis have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.3% of all adverse event reports for TOCILIZUMAB.

246
Reports of Bronchopulmonary aspergillosis with TOCILIZUMAB
0.3%
of all TOCILIZUMAB reports
120
Deaths
118
Hospitalizations

How Dangerous Is Bronchopulmonary aspergillosis From TOCILIZUMAB?

Of the 246 reports, 120 (48.8%) resulted in death, 118 (48.0%) required hospitalization, and 31 (12.6%) were considered life-threatening.

Is Bronchopulmonary aspergillosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 246 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Bronchopulmonary aspergillosis?

TACROLIMUS (968) PREDNISONE (967) DEXAMETHASONE (854) CYCLOPHOSPHAMIDE (824) METHYLPREDNISOLONE (794) PREDNISOLONE (704) MYCOPHENOLATE MOFETIL (702) RITUXIMAB (606) CYCLOSPORINE (583) METHOTREXATE (553)

Which TOCILIZUMAB Alternatives Have Lower Bronchopulmonary aspergillosis Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Bronchopulmonary aspergillosis Reports All Drugs Causing Bronchopulmonary aspergillosis TOCILIZUMAB Demographics